This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ye, C. Articles by Li, M. Search for Related Content PubMed PubMed Citation Articles by Ye, C. Articles by Li, M.

Antiangiogenic and Antitumor Effects of Endostatin on Follicular Thyroid Carcinoma

Department of Vascular Surgery (C.Y., C.F., S.W., Y.L.), The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, Guangdong 510075, China; and University of Pittsburgh Cancer Institute and Department of Pathology (C.Y., C.F., X.L., M.L.), University of Pittsburgh School Medicine, Pittsburgh, Pennsylvania 15213

Address all correspondence and requests for reprints to: 200 Lothrop Street, Biomedical Science Tower, Room W955, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213. E-mail: mengfeng{at}pitt.edu.

Tumor growth and metastasis depend on blood supply and blood vessel formation. Angiogenesis, therefore, represents a promising target for cancer therapy. Endostatin is one of the most potent antiangiogenic factors and has been shown to effectively inhibit angiogenesis and tumor growth in a variety of in vivo models. In this study, we tested the effects of endostatin on xenografted human follicular thyroid carcinoma (FTC) in nude mice. Our result demonstrated that recombinant endostatin significantly inhibited the growth of FTC xenografts. Furthermore, we established an endostatin-expressing FTC cell line (FTC-BmEndo) using retrovirus-mediated gene transfer approach. We found that the in vivo growth of FTC-BmEndo cells was significantly inhibited, compared with the parental FTC cells, whereas both lines grew at the same rate in vitro. High-level expression of endostatin within the FTC-BmEndo tumors was evidenced by immunohistochemical staining, paralleled with a reduced microvessel density. The systemic level of vascular endothelial growth factor was significantly lower in mice bearing the FTC-BmEndo tumors than in those bearing parental FTC tumors. By using two different approaches, namely the recombinant endostatin protein and the gene therapy strategy, our study demonstrated that endostatin could be effective in suppressing the growth of human FTC in immunodeficient mice.

This article has been cited by other articles:

				S. Hoffmann, A. Wunderlich, S. Lingelbach, P. B. Musholt, T. J. Musholt, R. von Wasielewski, and A. Zielke Expression and Secretion of Endostatin in Thyroid Cancer Ann. Surg. Oncol., December 1, 2008; 15(12): 3601 - 3608. [Abstract] [Full Text] [PDF]

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				A. Lyshchik, R. Moses, S. L. Barnes, T. Higashi, R. Asato, M. I. Miga, J. C. Gore, and A. C. Fleischer Quantitative Analysis of Tumor Vascularity in Benign and Malignant Solid Thyroid Nodules J. Ultrasound Med., June 1, 2007; 26(6): 837 - 846. [Abstract] [Full Text] [PDF]

				M. N. Younes, Y. D. Yazici, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3425 - 3434. [Abstract] [Full Text] [PDF]

				H. De Nicola, J. Szejnfeld, A. F. Logullo, A. M. B. Wolosker, L. R. M. F. Souza, and V. Chiferi Jr Flow Pattern and Vascular Resistive Index as Predictors of Malignancy Risk in Thyroid Follicular Neoplasms J. Ultrasound Med., July 1, 2005; 24(7): 897 - 904. [Abstract] [Full Text] [PDF]

				M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al. Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation Cancer Res., June 1, 2005; 65(11): 4716 - 4727. [Abstract] [Full Text] [PDF]

				C. Ye, C. Feng, S. Wang, K. Z. Q. Wang, N. Huang, X. Liu, Y. Lin, and M. Li sFlt-1 Gene Therapy of Follicular Thyroid Carcinoma Endocrinology, February 1, 2004; 145(2): 817 - 822. [Abstract] [Full Text] [PDF]

				E. L. Davies, J. D. Ramsden, H. Cocks, P. F. Searle, J. C. Watkinson, H. Ueno, A. Logan, J. A. Franklyn, V. Mautner, and M. C. Eggo Adenovirus-Mediated Expression of Dominant Negative Fibroblast Growth Factor (FGF) Receptor 1 in Thyroid Cells Blocks FGF Effects and Reduces Goitrogenesis in Mice J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4472 - 4480. [Abstract] [Full Text] [PDF]